Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00041301
Status:
COMPLETED
Last Update Posted:
2012-08-27
First Post:
2002-07-08
Brief Title:
Assessing Quality of Life of Patients With Prostate Cancer
Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC
Organization:
European Organisation for Research and Treatment of Cancer - EORTC
Study Overview
Official Title:
An International Field Study Of The Reliability And Validity Of The EORTC QLQ-C30 And A Disease-Specific Questionnaire Module QLQ-PR25 For Assessing Quality Of Life Of Patients With Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate and long-term effects of the treatment on these patients
PURPOSE Clinical trial to study the effectiveness of two questionnaires in assessing quality of life of patients who have prostate cancer
PURPOSE Clinical trial to study the effectiveness of two questionnaires in assessing quality of life of patients who have prostate cancer
Detailed Description:
OBJECTIVES
Assess the scale structure psychometric validity and reliability of quality of life measurements using the EORTC QLQ-C30 and the prostate cancer-specific QLQ-PR25 questionnaires in patients with stage I-IV prostate cancer
OUTLINE This is a multicenter study Patients are stratified according to stage of disease local or locally advanced disease vs metastatic disease
Patients complete EORTC QLQ-C30 and prostate cancer-specific QLQ-PR25 questionnaires before therapy and at 3 months after the start of therapy Patients in stratum II also complete questionnaires at 6 months after the start of therapy
PROJECTED ACCRUAL A total of 375 patients will be accrued for this study
Assess the scale structure psychometric validity and reliability of quality of life measurements using the EORTC QLQ-C30 and the prostate cancer-specific QLQ-PR25 questionnaires in patients with stage I-IV prostate cancer
OUTLINE This is a multicenter study Patients are stratified according to stage of disease local or locally advanced disease vs metastatic disease
Patients complete EORTC QLQ-C30 and prostate cancer-specific QLQ-PR25 questionnaires before therapy and at 3 months after the start of therapy Patients in stratum II also complete questionnaires at 6 months after the start of therapy
PROJECTED ACCRUAL A total of 375 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EORTC-30011 | OTHER | EORTC | None |
| EORTC-15011 | OTHER | None | None |